Oncology Based In-vivo CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft), By Region and Competition 2020-2030F

Market Overview

Oncology Based In-vivo CRO Market has valued at USD 1.24 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 8.29% through 2030F. The oncology-based in vivo Contract Research Organization (CRO) market is a dynamic and rapidly evolving sector that bridges healthcare, biomedical research, and pharmaceutical development. It plays a crucial role in supporting the discovery and development of novel cancer therapies by providing specialized services for preclinical and clinical studies conducted in living organisms. This market has gained significant momentum due to the rising global incidence of cancer and the urgent need for more targeted, effective treatment options.

In vivo CROs enable pharmaceutical and biotechnology companies to streamline drug development processes, reduce time-to-market, and manage costs more efficiently by offering comprehensive testing models and regulatory expertise. The sector is further driven by remarkable technological advancements, including high-resolution imaging systems, humanized mouse models, and the integration of artificial intelligence for predictive modeling. Personalized medicine is also reshaping the landscape, with in vivo CROs adapting to tailor therapies based on patient-specific genetic and molecular profiles. Moreover, collaborations between CROs, academic institutions, and healthcare providers are expanding research capabilities and facilitating innovation. As oncology continues to be a primary focus in drug development pipelines, the in vivo CRO market is poised for sustained growth, playing a vital role in transforming cancer treatment and improving patient outcomes globally. For instance, Crown Bioscience has expanded its Singapore facility with advanced oncology models and cutting-edge imaging technologies, strengthening its role in the oncology-based in vivo CRO market. This upgrade enhances support for global and local biotech and pharmaceutical companies focused on preclinical and translational oncology drug development in Asia’s biomedical hub.

Key Market Drivers

Rising Prevalence of Cancer

The relentless rise in cancer incidence has propelled the oncology-based in vivo Contract Research Organization (CRO) market into a dynamic phase of growth. For instance, according to WHO 2024, in 2022 there were 20 million new cancer cases and 9.7 million deaths. Around 53.5 million people were living within five years of a cancer diagnosis. Cancer affects 1 in 5 people globally, with higher mortality among underserved populations, highlighting urgent health equity challenges. As cancer continues to exert an alarming global impact, there is an escalating demand for swift and precise solutions, spurring a surge in research and development activities. This surge, in turn, fuels the need for specialized services provided by in vivo CROs. With the intricacies of cancer biology and treatment modalities constantly evolving, pharmaceutical and biotechnology companies increasingly rely on these CROs to conduct intricate preclinical and clinical studies. The complexity of cancer research requires a multidisciplinary approach, and in vivo CROs are adept at providing the essential tools, expertise, and resources to accelerate the development of innovative therapies. As personalized medicine gains traction, tailoring treatments to individual genetic profiles necessitates sophisticated research techniques offered by these CROs. Moreover, the competition to bring novel therapies to the market drives the outsourcing trend, as companies seek to streamline operations and enhance efficiency. In a landscape characterized by rapid advancements in genomics, imaging technologies, and data analytics, in vivo CROs play an indispensable role in facilitating groundbreaking discoveries. Ultimately, the surging tide of cancer cases has not only heightened the demand for effective treatments but has also become a powerful catalyst for the expansion and diversification of the oncology based in vivo CRO market, propelling it into a pivotal position at the forefront of the fight against this formidable disease.

Advancements in Cancer Research

The ever-evolving landscape of cancer research is wielding a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. With each stride in our understanding of cancer biology, genetics, and treatment mechanisms, the demand for highly specialized research services provided by in vivo CROs surges. As reported by UKRI, in October 2024, Innovate UK and the Office for Life Sciences (OLS) announced additional funding to boost innovation in cancer treatment. Under the Advancing Precision Medicines competition, they committed USD 4.2 million to support six new projects. This investment aligns with the Life Sciences Vision Cancer Mission and follows the 2023 initiative, where seven cancer-focused projects received a total of USD 4.73 million in funding. Advancements in areas such as immunotherapy, targeted therapies, and precision medicine have transformed the oncology field, necessitating more intricate and tailored studies. In vivo CROs possess the expertise and cutting-edge technologies required to conduct complex preclinical and clinical investigations that align with these breakthroughs. As new avenues for treatment emerge, pharmaceutical and biotechnology companies are increasingly turning to these CROs to expedite drug development processes and ensure the safety and efficacy of their therapies. The intricate interplay between genetics, tumor microenvironments, and therapeutic responses mandates a comprehensive and multidimensional approach to research, and in vivo CROs are poised to fulfill this role adeptly. Furthermore, the competitive drive to be at the forefront of innovative cancer treatments has spurred companies to outsource research activities to specialized partners, contributing to the expansion of the CRO market. In an era characterized by rapid scientific progress, the symbiotic relationship between advancements in cancer research and the growth of the oncology based in vivo CRO market is poised to forge a transformative path forward in the fight against cancer.

Download free Sample Report

Key Market Challenges

Complexity of Cancer Research

The intricate nature of cancer research stands as a formidable obstacle impeding the growth of the oncology-based in vivo Contract Research Organization (CRO) market. The multifaceted challenges posed by the diversity of cancer types, intricate genetic variations, and evolving treatment paradigms demand a level of specialized expertise that few can provide. Conducting accurate and comprehensive in vivo studies that mirror the complex reality of cancer within living organisms requires sophisticated methodologies and equipment, which can strain the resources of both CROs and their clients. Moreover, the need to keep abreast of rapidly advancing scientific discoveries adds another layer of complexity. Ensuring that in vivo studies effectively capture the intricate interplay of genetic factors, tumor microenvironments, and treatment responses necessitates a multidimensional approach that requires not only cutting-edge technologies but also a deep understanding of cancer biology. As such, the complexity of cancer research can hinder the growth of the in vivo CRO market by limiting the pool of experts, increasing costs, and elongating project timelines, thereby underscoring the critical need for sustained innovation and collaboration within the field.

High Costs

The soaring costs associated with oncology-based in vivo Contract Research Organization (CRO) services pose a significant barrier to the market's expansion. Conducting comprehensive in vivo studies demands advanced equipment, skilled personnel, and substantial resources, resulting in elevated project costs. These expenses can deter smaller pharmaceutical and biotech companies, as well as research institutions with limited budgets, from accessing the expertise and services offered by in vivo CROs. Moreover, the high costs can also lead to increased pricing for services, potentially making them unaffordable for certain clients. This financial strain can curtail research and development efforts, slow down the pace of drug discovery, and limit the industry's ability to accommodate a broader range of projects. As such, addressing the issue of high costs is pivotal for fostering a more accessible and vibrant oncology based in vivo CRO market, enabling diverse entities to harness the specialized capabilities required to advance our understanding and treatment of cancer.

Key Market Trends

Personalized Medicine

The paradigm shift towards personalized medicine is exerting a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As medical science increasingly recognizes the unique genetic and molecular profiles that underlie individual patients' responses to treatments, the demand for highly tailored research and preclinical studies has surged. In vivo CROs are at the forefront of this transformative trend, enabling the creation of animal models that closely mimic patients' genetic characteristics. These models allow for precise evaluations of potential therapies, predicting their effectiveness and potential side effects in specific patient populations. The intricate interplay between genetic factors, tumor microenvironments, and treatment responses necessitates nuanced research methodologies, and in vivo CROs possess the expertise and cutting-edge technologies required to execute such studies. With the goal of developing treatments that are optimally effective and minimally toxic for each patient, pharmaceutical and biotech companies are increasingly relying on in vivo CROs to conduct studies that bridge the gap between preclinical research and clinical trials. As personalized medicine gains momentum, the strategic role of in vivo CROs in shaping the landscape of oncology research and therapy development becomes ever more pronounced, solidifying their pivotal contribution to the advancement of precision cancer care.

Digitalization and Data Analytics

The rapid integration of digitalization and data analytics is wielding a transformative impact on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As cancer research becomes increasingly data driven, in vivo CROs are leveraging advanced technologies to enhance the efficiency, accuracy, and depth of their studies. Real-time monitoring, high-resolution imaging, and sophisticated data analysis tools enable a comprehensive understanding of cancer biology, treatment responses, and disease progression. This digital revolution empowers researchers to extract meaningful insights from complex datasets, identifying subtle patterns and correlations that were previously elusive. In vivo CROs equipped with these capabilities can offer a comprehensive view of how potential therapies interact with living organisms at molecular and cellular levels, paving the way for more informed decision-making during drug development. Additionally, the integration of digital tools facilitates remote monitoring and collaboration, allowing researchers to conduct studies across geographical boundaries. This not only accelerates research timelines but also opens doors to global partnerships and client collaborations. As the demand for precise and data-rich insights in oncology research intensifies, in vivo CROs adept in harnessing digitalization and data analytics are poised to drive advancements in our understanding of cancer and propel the development of more effective therapies, solidifying their pivotal role in the dynamic landscape of oncology research.

Segmental Insights

Indication Insights

Based on indication, the solid tumors segment dominates the Oncology Based In-vivo CRO market and is predicted to continue expanding over the coming years. Solid tumors have emerged as dominant players in the oncology-based in vivo Contract Research Organization (CRO) market due to their prevalence and complex nature. These tumors, characterized by their cohesive mass of cells, represent a significant portion of cancer cases, driving the demand for specialized research services provided by in vivo CROs. Given the intricate interplay of genetic mutations, microenvironmental factors, and treatment responses within solid tumors, preclinical studies conducted by in vivo CROs are essential for evaluating potential therapies. As the understanding of solid tumor biology and targeted therapies advances, pharmaceutical and biotech companies increasingly rely on these CROs to conduct comprehensive studies that inform clinical trial design and decision-making. The specialized expertise of in vivo CROs in creating accurate animal models and conducting sophisticated analyses aligns with the intricacies of solid tumor research, establishing them as pivotal contributors in advancing our ability to combat these formidable diseases.

Download free Sample Report

Regional Insights

The North America region has established itself as the leader in the Oncology Based In-vivo CRO Market with a significant revenue share in 2024. North America has emerged as the leader in the Oncology Based In-vivo Contract Research Organization (CRO) market due to a combination of advanced healthcare infrastructure, robust research funding, and the presence of major pharmaceutical and biotechnology companies. The region, particularly the U.S., boasts a high prevalence of cancer, driving demand for innovative oncology solutions. Additionally, strong support from government bodies like the NIH and FDA accelerates clinical trials and regulatory approvals. North America is home to top-tier CROs offering specialized in-vivo oncology services, backed by cutting-edge technologies and skilled professionals. Academic institutions and cancer research centers also collaborate actively with CROs, enhancing the pace of drug development. Moreover, favorable reimbursement policies and a high awareness of clinical research among patients contribute to a steady pipeline of trial participants. Together, these factors create a conducive ecosystem, positioning North America at the forefront of the oncology in-vivo CRO landscape.

Recent Developments

• In October 2024, Crown Bioscience, a San Diego-based global CRO, in partnership with JSR Life Sciences and JSR Corporation of Japan, announced the expansion of its Singapore facility. The upgrade includes advanced oncology research models and state-of-the-art imaging technology, enhancing its capabilities in cancer research and drug development.
• In November 2023, Charles River Laboratories partnered with Aitia, granting Aitia access to Logica, Charles River’s AI-driven drug development platform. This collaboration aimed to accelerate the discovery and early development of oncology and neurodegeneration therapeutics, particularly for less complex programs.
• To enhance the commercialization and development of the OmniCAR cell therapy technology, Thermo Fisher Scientific Inc. and Prescient Therapeutics established a partnership in August 2022. This agreement would evaluate the potential of using automated closed-cell therapy options to develop a special method for making cell treatments on the OmniCAR platform without the usage of viruses.
• Elicio Therapeutics received a USD 2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago in September 2022 to support the development of two therapeutic cancer vaccines. While ELI-008 is being developed to target p53 hotspot mutations in solid tumours such colorectal cancer, melanoma, and non-small cell lung cancer (NSCLC), ELI-007 is being developed to target BRAF gene alterations. As a result, the COVID-19 pandemic has influenced the in-vivo CRO market for oncology.
• Bioanalytical Systems, Inc. debuted Inotiv, its new brand for contract research services, in November 2021. Beginning with in vivo toxicology, pharmacology, bioanalysis, drug metabolism, and pharmacokinetic solutions, Inotiv began representing the unification of the business' Seventh Wave Laboratories & Smithers Avanza Toxicology Services.

Key Market Players

• Charles River Laboratories, Inc.
• ICON PLC
• Thermo Fisher Scientific Inc.
• Eurofins Scientific SE
• Taconic Biosciences, Inc.
• Crown Biosciene, Inc.
• LabCorp
• WuXi AppTec Co., Ltd.
• Evotec SE
• The Jackson Laboratory

Report Scope:

In this report, the global Oncology Based In-vivo CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Oncology Based In-vivo CRO Market, By Indication:

o   Blood Cancer

o   Solid Tumor

• Oncology Based In-vivo CRO Market, By Model:

o   Syngeneic Model

o   Patient Derived Xenograft

o   Xenograft

• Oncology Based In-vivo CRO Market, By Region:

o   North America

o   Europe

o   South America

o   Asia Pacific

o   Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Oncology Based In-vivo CRO Market.

Available Customizations:

Oncology Based In-vivo CRO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Oncology Based In-vivo CRO Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com